This is the authors' abstract. We don't add key points for this paper.
Background Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes and pessimism than healthy individuals and these biases are correlated with depression severity. Psilocybin has demonstrated sustained remission in MDD. Methods Secondary analysis of a two-arm, randomized controlled trial ( ClinicalTrials.gov Identifier: NCT03429075 ) assessing the effect of psilocybin therapy versus escitalopram on ‘maladaptive’ cognitive biases relevant to the construct of depression. Psilocybin group participants received two 25mg doses and escitalopram group received three weeks of daily 10mg, increased to 20mg for a following three weeks. Primary outcomes in this analysis were post-treatment changes in biases at six weeks compared with baseline, as measured using three validated psychological scales. Findings Fifty-nine MDD patients were randomly allocated to the psilocybin (n=30) or escitalopram (n=29) groups. Self-reported optimism showed a large and significant increase six-weeks after psilocybin treatment ( M diff =6·63 p <0·0001; 95% CI [4·06, 9·20], d= 1·1), whereas there was no change following escitalopram ( M diff =1·52, p =0·205; 95% CI [−0·59, 3·62], d= 0·4). Behavioral results found that patients were more optimistic about desirable life events after psilocybin treatment ( M diff =0·16, p =0·0002; 95% CI [0·08, 0·23], d= 1·1), but they were also less pessimistic about negative life events after escitalopram treatment ( M diff =0·07, p =0·018; 95% CI [0·01, 0·13], d= 0·5). We found improvements in all three domains of dysfunctional attitudes following psilocybin treatment: achievement ( M diff =10·37, p <0·0001; 95% CI [6·38, 14·53], d= 1·0); dependency ( M diff =7·97, p <0·0001; 95% CI [4·00, 11·93], d= 0·9) and self-control ( M diff =6·40, p =0·0006; 95% CI [2·60, 10·20], d= 0·8)), whereas only the achievement domain improved after escitalopram ( M diff =4·10, p =0·005; 95% CI [1·35, 6·86], d= 0·6). Interpretation These results suggest that two high-dose sessions with psilocybin therapy are superior to a six-week daily course of a selective serotonin-reuptake inhibitor antidepressant, in remediating negative cognitive biases in depression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Henry et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: